Podcasts about mounjaro

Weight loss injections are a huge story in the diet world right now. This is a special episode of the podcast, where we hear from people who have experience of using the Mounjaro and Wegovy jabs. You'll get stories from people have had good, bad and every other kind of experience with injections. Some of our contributors have got their jabs via the NHS, others have sourced them privately. We have information about the costs involved, should you want to do the same. Plus we hear from people who have chosen not to try the jabs and why. Send us a voicenote: 07468 286104 If you'd like to mark your weight loss with our exclusive certificates, get Extra Portions of this podcast and win CASH PRIZES go to patreon.com/noshameinagain or find us on the Patreon app. Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Irresistible You podcast, we're diving into what it means to embrace your cozy or “soft life” era, without the guilt. I used to think that doing cozy things like diamond painting or relaxing at home was lazy… or worse, that stillness would lead to weight gain. I thought if it didn't make money or burn calories, it was a waste of time. But now I know better.I'm sharing how I've started doing things that pull me rather than constantly pushing myself and how that shift has helped me stop emotional eating, feel more grounded, and finally listen to my body. Cozy isn't laziness, it's restoration.If you've ever felt stuck between hustle culture and burnout, this episode is for you.

Still unsure about weight loss injections? They've been around for a while now.  So I thought it would be a good idea to get Dr Aamina on the podcast to explain more about them.  At the end of this episode, you will have a lot more clarity as to what these are, and whether they will benefit youP.S - Whenever you are ready, get in touch with us and let us fast-track your progress!

Den senaste månaden har det kommit mycket nyheter när det gäller olika typer av fetmamediciner och Jacob och Erik ger dig därför en genomgång av det om de bedömer är bra att känna till både kring ny data för redan godkända mediciner och ny information kring fetmamediciner om troligen kommer att finnas på marknaden inom några år. På Hälsoveckan by Tyngres instagram kan du hitta bilder relaterat till detta och tidigare avsnitt. Hålltider (00:00:00) Introsnack (som är lite gammalt) (00:02:38) Fetmamedicinerna på marknaden och det som troligen är på väg in på marknaden (00:04:51) Semaglutid i tablettform lär godkännas vid fetma framöver (00:07:22) Tirzepatid, mer känd som Mounjaro (00:08:31) Även Tirzepatid är på väg att släppas i tablettform (00:11:15) Om biverkningarna man känner till och eventuell risk för nya, ännu okända biverkningar (00:17:32) Cagrisema - funkar bra men fick ändå Novo Nordisk aktie att crasha (00:20:20) Rretatrutide - just nu mest imponerande resultat men bara fas 2 (00:22:59) Maridebart Cafraglutide - endast en injektion i månaden (00:26:47) Amykretin - Ny medicin från Novo Nordisk som verkar bättre än Cargisema (00:27:41) Myostationhämmare tillsammans med viktnedgångsmediciner (00:38:17) Två läkemedel från kinesiska företag är nära godkännande där (00:41:31) Novo Nordisk har glömt att förlänga sin patent i Kanada (00:42:18) Två läkemedel som än så länge bara testats i fas 1 (00:43:33) De redan etablerade medicinerna testas i fas 3 mot olika sjukdomar

Welcome to my Summer Throwback Playlist—a handpicked collection of the most downloaded episodes of the podcast. These are listener favorites, packed with insights, laughs, and empowered eating encouragement to keep you fueled all summer long. A quick heads up: since these are throwbacks, you might hear old references to programs or events that are no longer active—but the heart of each episode still hits. Let's dive in and revisit the best of the best! In this episode, we're diving into one of the most talked-about weight loss medications on the market: Ozempic—also known by names like Wegovy and Mounjaro. You've likely seen the buzz: celebrity endorsements, dramatic TikTok before-and-afters, and headlines calling it a “miracle drug.” I've had clients take it, ask about it, swear by it, and question it. I've also heard from colleagues with very strong opinions on both sides. So, what's the truth? What is Ozempic really designed for? How does it work? Does it actually help with weight loss? And most importantly—is it safe? I'm sharing a brief overview of the science, my clinical observations, and why this conversation matters—especially in a world where body image, quick fixes, and long-term health often clash. ⚠️ Trigger Warning: If you're currently struggling with or recovering from an eating disorder, please listen with care or consider skipping this episode. Ozempic is contraindicated for anyone with a history of eating disorders. Want to go deeper? I reference two excellent episodes that continue this conversation: "Science Vs." and "Honestly".

What if We're Using GLP-1 Medications All Wrong?Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we're not harnessing their full therapeutic potential?In this eye-opening conversation, Dr. Ben Bikman, metabolic health researcher and professor at BYU, joins Dr. Bret Scher to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health.Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach:Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbsUsing the medication as a temporary metabolic tool to support transitions to lower-carb dietsReducing long-term risks such as muscle loss, mood changes, and diminishing effectivenessEmphasizing the importance of habit change, insulin regulation, and muscle preservationThis conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies.

Dr. Andrew Rochford joins the show to give an anonymous host some advice on Mounjaro overdosing and how to stay on top of you and your family's health this winter. Meanwhile, Wippa makes a bold prediction—that everyone will have superpowers within the next five years.See omnystudio.com/listener for privacy information.

Broadcast from KSQD, Santa Cruz on 7-10-2025: Dr. Dawn responds to an email about lion's mane mushroom blood thinning properties. Lion's mane contains hericenones that inhibit platelet aggregation but promote nerve cell growth. People on blood thinners like Eliquis or those with bleeding disorders should stop these supplements before surgery. She recommends lion's mane for cognitive preservation effects despite bleeding risks, emphasizing the need to balance benefits versus risks. An emailer asks about Fatty15 (C15:0 pentadecanoic acid) supplements marketed for longevity. Dr. Dawn finds promising research, however, most studies are in animals with limited human data. She warns against over-supplementation and recommends food-first approaches, suggesting cheaper alternatives like berberine may provide similar benefits. A visiting guest asks about continuing L-arginine after blood pressure normalized. Dr. Dawn recommends continuing L-arginine as it helps produce nitric oxide and prevents age-related arterial stiffening. She explains how blood vessel elasticity decreases with age, creating feed-forward cycles leading to permanent hypertension. The guest also asks about iodine safety - Dr. Dawn confirms 1mg daily is safe, noting Japanese populations consume up to 4mg daily without problems. Another visiting guest inquires about memory-boosting supplements (nootropics). Dr. Dawn identifies nicotine and caffeine as effective options, mentioning she uses nicotine patches for test-taking focus. She discusses lion's mane as effective for cognitive enhancement and coffee blends combining both ingredients. A caller asks about tirzepatide (Mounjaro) for weight loss at age 73, concerned about muscle loss. Dr. Dawn emphasizes the importance of branched-chain amino acids and 20-30 grams of protein before exercise for older adults to build muscle protein. She explains younger people can build muscle while fasting, but older adults need circulating protein during exercise to activate muscle-building DNA. She recommends alternating upper and lower body workouts and checking testosterone levels. Another caller asks about rapid resting pulse rate (80-100 bpm) at age 74. Dr. Dawn suggests checking blood pressure, as low blood pressure can cause compensatory heart rate increases. She explains age-related changes in blood vessel reflexes that can cause blood pooling in legs and orthostatic changes. The caller also complains about pharmaceutical advertising, prompting Dr. Dawn to criticize direct-to-consumer drug marketing for creating artificial needs through emotional manipulation. Dr. Dawn warns against P-Tau217 blood testing for Alzheimer's screening, calling it inadequate for general population screening. The test has poor predictive value below level 10, creating many false positives in low-risk populations. She criticizes associated drugs like donanemab (Kisunla) for severe side effects including brain swelling and hemorrhage. Instead, she recommends lifestyle interventions: exercise, stress control, adequate sleep, reduced alcohol and sugar intake for memory concerns. She criticizes FDA approval of a new blood test for colon cancer screening with 83% sensitivity for detecting existing cancers but poor sensitivity for precancerous polyps. Dr. Dawn criticizes this as inadequate screening since it detects cancer after "the horse has left the barn" rather than preventing it. In closing remarks with her impromptu guests, Dr. Dawn addresses a question about intermittent fasting and exercise timing. She explains that exercising while fasting provides cardiovascular benefits but won't build muscle mass in older adults. She recommends bioimpedance analysis testing to track lean body mass annually in seniors and emphasizes the importance of progressive resistance training to prevent age-related muscle loss.

Ozempic continues to dominate conversations about weight loss, drawing attention from both the medical community and celebrity circles over the past week. This injectable medication, originally designed to manage type two diabetes, has increasingly become known for its ability to help people shed pounds. According to information from Northwestern University published just yesterday, users of Ozempic typically see a gradual but significant reduction in body weight, with clinical trials showing average losses of ten to fifteen percent over the course of a year. For most, the medication begins to make a noticeable difference after about six to eight weeks, particularly when combined with improved diet and regular exercise. However, experts are quick to caution that Ozempic is not a magic solution; sustainable weight loss still relies on lifestyle changes such as healthy eating and physical activity.In the last week, the public conversation around Ozempic has taken on new dimensions. One of the most visible aspects is its popularity among celebrities. According to coverage in the Financial Express from July seventh, high-profile users like Oprah Winfrey, Sharon Osbourne, Whoopi Goldberg, and Rebel Wilson have shared their experiences with Ozempic. Their stories have contributed to the drug's reputation as Hollywood's preferred method for rapid, dramatic weight reduction. However, this visibility has also drawn attention to some unexpected consequences. Dermatologists report an uptick in people experiencing what is now being called Ozempic mouth, a condition marked by significant volume loss and increased wrinkles around the mouth and jawline, which can result in an aged appearance. The rapid loss of facial fat has caused some to seek cosmetic treatments like dermal fillers or skin-tightening procedures to counteract these effects.Oprah Winfrey has been especially vocal and candid about her Ozempic journey in the past week. Reports from Deaconess Health and SheFinds note that Oprah has discussed the medication's role in her recent forty-pound weight loss, which she has attributed to Ozempic, healthy eating, and consistent exercise. During her recent trip to Venice for a celebrity wedding, Winfrey was photographed sporting a noticeably slimmer physique while working out with Gayle King. Fans on social media praised her transformation, and Winfrey herself has emphasized the importance of pairing any medication with dedication to overall well-being. Furthermore, Oprah recently hosted a "State of Weight" panel as part of her ongoing efforts to foster open discussion about weight loss, the struggles involved, and the tools that can help.While Ozempic maintains its position as a popular weight loss solution, new research published in The New England Journal of Medicine and reported by both HealthDay and AOL this week has challenged its supremacy. The study found that another medication, tirzepatide sold under the names Mounjaro and Zepbound, is even more effective at promoting weight loss. Participants taking tirzepatide averaged a twenty percent reduction in body weight, while those on Ozempic averaged about thirteen percent. Experts note that tirzepatide works on two hormone receptors instead of one, which seems to explain its stronger effect. Despite these new findings, Ozempic's influence remains powerful because of its proven track record and cultural prominence.Still, significant safety concerns persist regarding Ozempic's use for weight loss. The Motley Rice law firm and other health sources have reported ongoing lawsuits related to serious side effects, including gastrointestinal issues and, in rare cases, vision loss. Moreover, many patients regain much of the weight they lost if they discontinue the medication, pointing to the need for ongoing management and support rather than quick fixes.In summary, the past week has seen Ozempic's celebrity power and medical potential both celebrated and scrutinized. Oprah Winfrey's openness continues to resonate with many, highlighting that while medications like Ozempic can be helpful tools, the broader journey of weight management demands a holistic approach. The emergence of alternatives such as tirzepatide may shift the landscape, but one message remains clear from experts and high-profile users alike: sustainable weight loss requires lasting lifestyle change, not just a prescription.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Uma descoberta surpreendente está emergindo entre usuários de medicamentos GLP-1 como Ozempic e Wegovy: essas drogas revolucionárias para perda de peso não apenas suprimem o apetite, mas estão alterando fundamentalmente como percebemos cheiros.Kara Nesvig, colecionadora de mais de 100 perfumes, descobriu que seus aromas favoritos - especialmente fragrâncias de baunilha que antes evocavam memórias românticas - começaram a provocar náuseas intensas após iniciar tratamento com semaglutida. Sua experiência não é isolada: milhares de usuários relatam mudanças olfativas dramáticas, desde aversão total a perfumes até "fome" por fragrâncias doces.A ciência por trás desse fenômeno é fascinante. O Dr. Hiroaki Matsunami, autoridade mundial em neurobiologia olfativa da Universidade Duke, explica que temos aproximadamente 1.000 tipos de receptores olfativos, cada um detectando moléculas específicas. Pesquisas recentes revelaram que o GLP-1 tem circuitos neurais separados no cérebro - alguns controlam saciedade sem aversão, outros desencadeiam forte repulsa.Cinco teorias científicas explicam as alterações: ruptura do sistema de recompensa cerebral, reprogramação de memórias olfativas, aversão condicionada similar à intoxicação alimentar, hipersensibilidade aos cheiros, e mudanças hormonais comparáveis à gravidez.Estudos controlados confirmam o fenômeno: 85% dos usuários de GLP-1 tiveram pontuações de paladar piores que controles, e paradoxalmente, aqueles com melhor olfato e paladar experimentam mais efeitos colaterais como náusea.A conexão com COVID-19 oferece insights valiosos - assim como o vírus causa alterações olfativas duradouras, os GLP-1 estão reescrevendo nossa percepção sensorial através de vias hormonais.Esta descoberta vai além da curiosidade: pode revolucionar tratamentos personalizados, ajudar no desenvolvimento de terapias para transtornos alimentares, e transformar nossa compreensão sobre como medicina, mente e memória se interconectam de formas surpreendentes.ReferênciasNesvig K. My GLP-1 Medication Changed the Way Perfume Smells to Me. Allure. 2025 Apr 17.Vaira LA, Hopkins C, Petrocelli M, Lechien JR, Chiesa-Estomba CM, Salzano G, et al. Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study. J Laryngol Otol. 2020;1-7. doi: 10.1017/S0022215120001826.Huang KP, Acosta AA, Ghidewon MY, McKnight AD, Almeida MS, Nyema NT, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024 Aug;632(8025):585-593. doi: 10.1038/s41586-024-07685-6.Han YE, Kang CW, Oh JH, Park SH, Ku CR, Cho YH, et al. Olfactory Receptor OR51E1 Mediates GLP-1 Secretion in Human and Rodent Enteroendocrine L Cells. J Endocr Soc. 2018 Nov;2(11):1251-1258. doi: 10.1210/js.2018-00165.Matsunami Lab. Duke University Department of Neurobiology. Disponível em: https://www.neuro.duke.edu/research/faculty-labs/matsunami-labKhan R, Doty RL. GLP-1 receptor agonists significantly impair taste function. Physiol Behav. 2024. doi: 10.1016/j.physbeh.2024.114XXX. [Artigo no prelo - ScienceDirect]Fournel A, Marlin A, Abot A, Pasquio C, Cirillo C, Cansell C, et al. The local GLP-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice. Mol Metab. 2023 Jun;72:101717. doi: 10.1016/j.molmet.2023.101717.Ozempic users report surprising cravings for certain smells: Here's what to know. Fox News Health. 2025 Jun 5.Jensterle Sever M, et al. Semaglutide improves sense of taste in women with obesity. Apresentado em: ENDO 2024, Endocrine Society Annual Meeting; 2024 Jun 1; Boston, MA.Ozempic Breath: Can Weight Loss Drugs Cause Halitosis? Healthline. 2024 May 2.

In Broodje Jaap! hebben we het al vaker gehad over afslankmiddelen zoals Ozempic en Mounjaro – inmiddels bekende namen. Maar deze middelen zijn niet zonder risico. Je moet ze doorgaans levenslang gebruiken, en zodra je stopt, is de kans groot dat je weer aankomt. Bovendien weten we nog weinig over de langetermijneffecten, zowel de mogelijke voordelen als de nadelen. Zo zijn er aanwijzingen dat het risico op een alvleesklierontsteking toeneemt. Reden genoeg voor de Britse toezichthouder op geneesmiddelen en medische hulpmiddelen om een studie te starten naar de bijwerkingen van deze zogenoemde ‘skinny jabs'. Maar ook over het gepolariseerde debat over dit onderwerp. Dit en meer hoor je in het laatste broodje van dit seizoen. Broodje Jaap!: iedere woensdag bellen we met prof.dr. ir. Jaap Seidell en nemen we de week door. We blikken vooruit, maar kijken ook terug. In 15 minuten nemen we dit met je door. Elke week opnieuw! I'm a Foodie is onafhankelijk en heeft geen banden met de voedingsindustrie. We ontwikkelen webinars, online masterclasses en schrijven boeken om jou te inspireren om gezonder te gaan eten. Je steunt ons door het kopen ervan.  Eet als een expert 2.0 is nu te bestellen in de pre-order! Klik op deze link. Een volledig vernieuwde versie van ons eerste boek (Eet als een expert, 2016) dat al 60.000 mensen hielp om gezonder en bewuster te eten. En nu zijn we terug met nóg meer inzichten, recepten en inspiratie. Eet als een expert 2.0 brengt rust en overzicht. Je leert wat écht werkt, gebaseerd op actuele wetenschap én onze jarenlange praktijkervaring met duizenden cliënten. Alleen tijdens de pre-order ontvang je de limited hardcover editie! Maar we maken dit boek niet alleen voor jou – we maken het ook met jou. Heb je wensen, ideeën of feedback? ​Laat het ons weten via dit formulier

Resources for the Community___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials United States Patent & Trademark Office Website and Email https://www.uspto.gov/usptoinfo@uspto.govi-MAK Websitehttps://www.i-mak.org/i-MAK Briefs & Reports https://www.i-mak.org/resource-type/briefs/______________________________________________________________________Tahir Amin, founder of I-MAK, joins us to break down why GLP-1 meds like Ozempic and Mounjaro stay so pricey. We dig into evergreening, patent thickets, and how pharma companies use legal loopholes to delay generics and extend monopolies.We also explore why some companies spend more on stock buybacks than drug innovation—and what that means for access. If you've felt exploited by the system, you're not alone. But there's hope. Learn about the policy changes ahead and how you can take action to fight for affordable meds.Tahir Amin bio:Tahir Amin is a founder and CEO of the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit organisation working to address the systemic inequities in how medicines are developed and distributed. He has over 30 years of experience in intellectual property (IP) law, during which he has practised with two of the leading IP law firms in the United Kingdom and served as IP Counsel for multinational corporations. His work focuses on changing the structural power dynamics that allow health and economic inequities to persist by challenging and re-shaping IP laws and the related global political economy to better serve the public interest.  He is a former Harvard Medical School Fellow in the Department of Global Health & Social Medicine and has served as legal advisor/consultant to many international groups, including the European Patent Office and World Health Organization, as well as testifying before the U.S. Congress on intellectual property and unsustainable drug prices.Special Guest Co-Host, Amanda Bonello from GLP-1 Collective https://glp1collective.org/ _______________________________Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro

Haben wir uns tatsächlich grundlos durch Brigitte-Diäten und David Kirsch-Eier gequält? Intervallfasten, Kohlsuppendiät, fettarme Leberwurst und Wandpilates – das soll alles umsonst gewesen sein? Der edelste Tropfen zwischen Hollywood und dem Main-Kinzig-Kreis heißt Mounjaro, Ozempic, Wegovy oder Saxenda. Für Adipositaspatient:innen rückt ein gesundes Gewicht in greifbare Nähe, Influencerinnen posten ihre mageren Schlüsselbeine. Also wo ist der Haken? Haben wir abgefragt. Wer bekommt die Spritze? Was ist mit Nebenwirkungen? Muss man das Zeug ewig nehmen? Ist Schlanksein jetzt was für Reiche? Wann gibt es das Zeug auf Rezept? Können Sportstudios jetzt dicht machen? Und ist die seidige Silhouette aus dem Kwikpen nur eine kurzfristige Modeerscheinung, oder können die Klamottenketten Größe 42 demnächst aus den Regalen räumen? Und wo zum Teufel ist denn Body Positivity hin? Diese Folge ist euer All Inclusive-Paket für alles rundum den sexy Body aus der Kanüle. Tanja Marfo postet seit Jahren Content rund um Selbstakzeptanz außerhalb des Normgewichts. Als sie selbst bei 240 Kilo war, hat sie die Notbremse gezogen. Erst ein Schlauchmagen, jetzt Mounjaro. Aber der Weg zu einem gesunden Gewicht ist deutlich schmerzhafter als ein kleiner Piks ins Bauchfett. Markus Grill hat zusammen mit dem Recherchenetzwerk von NDR, WDR und Süddeutscher Zeitung dem Phänomen Abnehmspritze auf den Zahn gefühlt. Warum sind so viele Medizinerinnen und Mediziner komplett aus dem Häuschen, wenns um diese Schlankmacher geht? Und was wäre, wenn's die Spritze auf Rezept gäbe? Spoiler: Wär gar nicht mal so geil. Dr. Andreas Klein ist Medizinethiker und gehört zum Zukunftsinstitut. Für ihn und seine Kolleg:innen ist die Abnehmspritze bereits die Zeitung von gestern. Seiner Meinung nach sind die Präparate gekommen, um zu bleiben. Aber wär das denn so schlimm? Ehrlicherweise sind wir ein bisschen stolz auf diese Folge. Macht es nicht kaputt! Und eins noch: Wir lieben jedes Pfund an euch! Und hier noch die Links fürs kleine Rabbit Hole vorm Schlafengehen: https://assets.ctfassets.net/sadqqidhqb2f/7revxW7gt8aDhDPwWmtfdN/149a4dfd7937eeeb1368ab7632b603bc/EFPIA_2024_Germany.pdf https://www.novonordisk.de/content/dam/nncorp/de/de/transparenz/2023/offenlegung-spenden-sonstige-2023-final-mzzu.pdf https://www.ndr.de/ratgeber/gesundheit/Ozempic-Fuer-wen-eignet-sich-die-Abnehmspritze-,adipositas170.html Und das hier legt euch vor allen Dingen Anne ans Herz, die eine parasoziale Beziehung mit Super Mario führt: Cheats https://www.ardaudiothek.de/sendung/cheats-wer-zerstoert-counter-strike/urn:ard:show:16d7f8950e911f8c/

Welcome to Ozempic Weightloss Unlocked, your source for the latest developments, insights, and real stories about Ozempic and the world of weight loss medications. Let's dive right in.The conversation around Ozempic remains as lively as ever in 2025. While Ozempic, or semaglutide, was originally created to manage type two diabetes, it quickly garnered attention for its remarkable ability to support significant weight loss. According to Toronto Life, this drug, which started as a diabetes treatment, has proven in multiple clinical trials to help some people lose up to twenty percent of their body weight when taken at higher doses, a result that validates obesity as a medical condition instead of just a lifestyle issue.A 2024 study highlighted by Drugs.com compared Ozempic to Mounjaro, another medication in the same class. Both were found effective, but Mounjaro showed even greater weight loss results, with eighty-two percent of patients losing at least five percent of their body weight, compared to sixty-seven percent for Ozempic. Importantly, these medications work by mimicking gut hormones to curb appetite and help with blood sugar control, but Mounjaro targets an additional hormone, which might explain the stronger effect.Clinical trials published in The Lancet have found participants using Ozempic experience an average drop of twelve to fourteen percent in body weight. And as reported by USF Blogs, real user stories show individuals can lose upwards of fifty pounds in a year, especially when combined with lifestyle changes. That brings us to a key point: Ozempic is most powerful when used alongside healthier eating and more physical activity. Fay Nutrition emphasizes that initial results might feel modest, with three to four percent weight loss in the first month for most people, but those who change their habits see the biggest long-term benefits.The rise of semaglutide-based treatments is fundamentally changing how health systems like the NHS treat obesity. In the United Kingdom, both Ozempic and its higher-dose sibling Wegovy are now routinely prescribed not just for diabetes but also for weight management. Over three million prescriptions are now issued annually in the NHS, making these drugs a staple of weight-related health care.But while the benefits are clear, there is growing attention on side effects and the need for responsible use. King Law reports that over eighteen hundred lawsuits have been filed in the United States, with issues ranging from slowed digestion to pancreatitis and even severe kidney injuries. The Food and Drug Administration has updated Ozempic's safety labeling to reflect these risks. Experts stress it is critical to use these drugs under proper medical supervision, especially with reports of non-doctors prescribing them illegally.On the medical front, research published in NEJM Evidence and covered by Live Science now suggests that semaglutide may benefit people with type one diabetes as well, broadening its potential impact in ways only just being explored.Beyond blood sugar and weight, Ozempic may also offer unexpected benefits. Dr. Aliabadi points out that some individuals report reduced cravings for alcohol while taking GLP-1 drugs, opening the door to new treatments for addiction in the future. The science is still developing, but it's another intriguing avenue for this class of medication.As new drugs like orforglipron enter the scene, delivering results that rival or surpass Ozempic, the landscape of medical weight loss continues to evolve rapidly. The one constant? While medications can be transformative, sustainable health always relies on a foundation of healthy choices and informed medical guidance.Thanks for joining us for another episode of Ozempic Weightloss Unlocked. Be sure to subscribe to stay up to date on the latest news, research, and real-life stories. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

This week, we're diving into the stories shaping what we eat, how we shop and the way we live. We're talking about the government's new push to tackle obesity by cutting just 50 calories a day, whether weight-loss jabs like Wegovy and Mounjaro are already changing our shopping habits, and the latest on possible bans or tighter rules for alcohol advertising in the UK. We also get into which oils you actually want to be cooking with at home, why M&S has just trademarked something called “Punishment Juice,” and a major new NHS survey that reveals one in four young adults are now living with a mental health condition. Plus, could creatine help prevent Alzheimer's? We look at what the science says so far — along with all our personal updates and this week's recommendations, from cult podcasts to berry-packed smoothies. This week's recs: Korean exfoliating mitt⁠ ⁠How I Became a Brainwashed Cult Bride⁠ on Conversations (ABC Australia) Get your copy of Rhi's new book 'The Unprocessed Plate' ⁠⁠HERE⁠ Vote for us to win the Listener's Choice award at the British Podcast Awards: https://www.britishpodcastawards.com/voting Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a message with this link, we would love to hear from you. Standard message rates may apply.On this episode discuss the side effects of GLP-1 medications like Ozempic and Wegovy, Zepbound, and Mounjaro offering practical strategies to manage these effects while still benefiting from the medications.• GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) help manage type 2 diabetes, obesity, and can reduce cardiovascular risk• Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, bloating, and constipation• "Sulfur burps" are a frequently reported side effect that some manage with Pepto-Bismol• Start with low doses and increase slowly to minimize side effects• Eat smaller portions, avoid greasy/spicy foods, and practice mindful eating to reduce GI symptoms• Stay hydrated and increase fiber intake to prevent constipation• Gallbladder problems and pancreatitis risk may increase with rapid weight loss• Some evidence suggests potential vision changes requiring regular eye check-ups• Medications like insulin or blood pressure drugs may need adjustment when on GLP-1s• Most side effects improve with time as your body adjusts to the medicationSend us an email at yourcheckuppod@gmail.com or visit our Instagram or website to stay updated with weekly episodes released every Monday.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Send us a textWhat happens when you've been using food to manage your emotions but, since you're on a GLP-1 medication, you can't do it anymore?Thanks for listening, I hope this episode will be helpful.Philippe

GLP-1 Weight Loss: Fat or Muscle? What Women Must KnowGLP-1 and the Skinny Fat Trap: How to Avoid Muscle LossAre GLP-1 weight loss drugs like Ozempic, Wegovy, or Mounjaro making you skinny fat? If you're seeing the scale go down—but losing strength, shape, and energy—you're not alone.In this video, I break down what the research really says about GLP-1 medications and why up to 40% of the weight lost may be from muscle, not fat. I'll also show you exactly how to protect your metabolism and stay strong during your weight loss journey.As an IFBB Fitness Pro and women's fitness coach with over 20 years of experience, I've helped thousands of women lose fat, build lean muscle, and feel confident in their bodies—at every stage of life, including menopause.✅ What you'll learn:- The truth about GLP-1 and muscle loss- How to avoid the “skinny fat” trap- The best strength training strategies- Protein goals that actually work- Recovery tips for better results- Why women over 40 need a different approach

Welcome to Ozempic Weightloss Unlocked, your source for the latest news, science, and lived experiences around Ozempic – and how it's transforming the landscape of weight management and health. Semaglutide, the active ingredient in Ozempic, began as a treatment for type two diabetes but quickly made waves for its powerful effect on weight loss. According to Yale University, Ozempic works by slowing stomach emptying and interacting with the brain's appetite regulation centers, naturally decreasing hunger and helping you feel fuller longer. Major clinical trials, as reported by the New England Journal of Medicine, found that people using Ozempic lost on average fifteen percent of their body weight over a sixty-eight-week period. That's a significant shift in the fight against obesity and has inspired a wave of success stories in 2025.Take Maria, a forty-two-year-old mother of two who, after years of struggling with different diets, lost thirty-five pounds in six months after her doctor prescribed Ozempic. She combined her medication with healthy foods and daily walks, gaining more energy and renewed self-confidence. John, a long-time executive living with type two diabetes, lost forty pounds and enjoyed not only improved blood sugar but the feeling of having his life back. Their stories, shared on Yale's health campus, point to the idea that consistency, a holistic approach, and strong support from healthcare professionals and family make all the difference.Ozempic doesn't just bring physical changes. Dr. Daniel Drucker, who helped develop GLP-1 medicines like Ozempic, told Toronto Life that the drug's success has helped validate obesity as a biological, not just behavioral, condition. For many, it's become proof that medical science can help overcome a complex health challenge – not just willpower alone.Globally, Ozempic and its sister drug, Wegovy, are reshaping national health systems like the NHS in the United Kingdom. NHS reports show over three million prescriptions for Ozempic issued annually, a testament to its popularity and potential. Wegovy, which is a higher-dose version designed specifically for weight loss, became available through specialist services in 2024. Healthcare leaders stress, however, that medications like Ozempic should support, not replace, good nutrition and regular activity. A combined approach delivers the best outcomes, and ongoing monitoring is essential to managing both progress and any possible side effects.Speaking of side effects, most users report mild-to-moderate gastrointestinal issues, especially at the start. There are still open questions about the long-term risks, and health authorities caution against unlicensed or cosmetic providers offering Ozempic outside proper medical supervision.In the competitive field of weight loss drugs, new challengers are emerging. According to Drugs.com and recent publications in JAMA Internal Medicine, Mounjaro, which combines GLP-1 and another gut hormone, has shown even greater weight loss than Ozempic in large studies. Nearly eighty-two percent of people using Mounjaro lost at least five percent of their body weight, compared to about sixty-seven percent for Ozempic. There's also a promising newcomer: a once-monthly shot called MariTide, which recent phase two trials show may rival or even exceed Ozempic's results, though it is not yet widely available.Looking ahead, Ozempic and its competitors are not just for type two diabetes or general obesity. A June 2025 study reported by Live Science found Ozempic's active ingredient may even help people with type one diabetes manage blood sugar and lose weight, hinting at a broader impact on medicine in the years to come.That wraps up this episode of Ozempic Weightloss Unlocked. Thank you for tuning in and remember to subscribe so you never miss an update. This has been a Quiet Please production, for more check out quietplease dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

GLP-1's are tools and if you don't use them well, there's a cost. I'm a registered dietitian, speaker and author who works in the weight loss and GLP-1 space. Here are the 3 most important nutrition pitfalls to avoid if you want to feel your best on a GLP-1 like Ozempic, Mounjaro, Zepbound, & Wegovy.

In this informative and compassionate episode, Bonnie breaks down the rising popularity of GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) specifically as they relate to weight loss. She dives deep into how they work, why they're being so widely prescribed, what the research actually says, and the often-overlooked risks and implications, especially around nutrition, food noise, and long-term health. Whether you're considering a GLP-1, currently on one, or feeling confused and conflicted, this episode offers grounded insights, body autonomy, and a non-judgmental space for informed decision-making.In this episode, you'll learn:How GLP-1 medications work to suppress appetite and delay stomach emptyingThe key difference in dosing between diabetes management and weight loss useWhy weight regain is common after stopping these medicationsThe connection between GLP-1 use, food noise, and eating disordersWhy prioritizing nutrition is critical—especially if you're using a GLP-1What this movement gets right—and what it missesRisks, side effects, and long-term unknowns of GLP-1 useHow to do a personal risk-benefit analysis rooted in body autonomyQuestions answered in this episode:What are GLP-1 medications, and why are they being used for weight loss?How do these drugs affect hunger, fullness, and food thoughts?Are there side effects or long-term risks with using GLP-1s for weight loss?What does the research actually say about their effectiveness and safety?Can these meds be harmful for someone with a history of disordered eating?What should I consider if I'm thinking about starting (or stopping) a GLP-1?How can I support a friend or loved one who is on one of these medications?Mentioned in this episode:Listen to episode 173: Quiet The Food Noise: 3 Ways Intuitive Eating Can HelpGLP-1 Informed Consent from Medical Students for Size Inclusivity DownloadFollow Regan Chastain's work: https://weightandhealthcare.substack.com/ Ready to Heal Your Relationship with Food?My team of registered dietitians is now accepting insurance for one-on-one nutrition counseling! Spots are limited, so if you're ready to start your journey toward food freedom, visit https://dietculturerebel.com/insurance to learn more!Connect with Bonnie on Instagram: @diet.culture.rebel

Is there a better, safer, FREE alternative to Ozempic (and other GLP-1 drugs)? In this episode of Walk, Don't Run to the Doctor, Miles Hassell MD reacts to the growing buzz and shares a time-tested, evidence-based 3-step plan that outperforms popular weight loss drugs in the long run. As GLP-1 drugs like Ozempic, Wegovy, and Mounjaro surge in popularity, Dr. Hassell offers critical insight into their risks—like muscle loss, pancreatic complications, and long-term unknowns—while proposing a practical, natural alternative for lasting weight loss and better metabolic health. Key Takeaways: Why Big Pharma's track record with weight loss drugs demands caution The secret 3-step plan: Eat 6 servings of fruits & veggies, 3 minutes of daily exercise, reduce refined carbs Bonus tips: Bust cravings by eating protein with every meal, daily probiotics, and unlock the power of preemptive eating Why this plan costs nothing, has zero side effects, and starts showing results in just one week A timely message in light of the weight loss drug headlines—who should be in control of your health?  More references can be found at www.GreatMed.org Get your copy of Good Food Great Medicine. https://a.co/d/ajAzYzo Would you like Dr. Hassell to answer your question on the air? Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter. We love to hear from you. This podcast is sponsored by our generous listeners. Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229 References: Chen, X., et al. (2025). Association of dietary fiber intake with all-cause and cardiovascular mortality in diabetes and prediabetes. Diabetology & metabolic syndrome, 17(1), 231. https://pubmed.ncbi.nlm.nih.gov/40533827/   Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism, 27(5), 2720–2729. https://pubmed.ncbi.nlm.nih.gov/39996356/   Wilding, J., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/   Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society, 8(11),https://pubmed.ncbi.nlm.nih.gov/39372917/    Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism, 26 Suppl 4, 16–27. https://pubmed.ncbi.nlm.nih.gov/38937282/   Sato, M., et al. (2023). Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study. Journal of clinical medicine, 12(9), 3104. https://pubmed.ncbi.nlm.nih.gov/37176545/   Monami, M., et al. (2017). Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes, obesity & metabolism, 19(9), 1233–1241. https://pubmed.ncbi.nlm.nih.gov/28244632/   Anderson, S. L., & Trujillo, J. M. (2010). Association of pancreatitis with glucagon-like peptide-1 agonist use. The Annals of pharmacotherapy, 44(5), 904–909. https://pubmed.ncbi.nlm.nih.gov/20371755/   Kapoor, I., Sarvepalli, S. M., D'Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of ophthalmology, 68(6), 1071–1083. https://pubmed.ncbi.nlm.nih.gov/37454782/   Bikou, A., et al. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert opinion on pharmacotherapy, 25(5), 611–619. https://pubmed.ncbi.nlm.nih.gov/38629387/   Jalleh, R. J., et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of clinical endocrinology and metabolism, 110(1), 1–15. https://pubmed.ncbi.nlm.nih.gov/39418085/   Berg, S. AMA. (2023). Questions patients may have about weight-loss drugs. https://www.ama-assn.org/delivering-care/public-health/questions-patients-may-have-about-weight-loss-drugs   Friedman, J. (2025). America's up-and-down history with weight-loss drugs. https://www.history.com/articles/weight-loss-drugs-america    

Sorry about the background noise. I will try to record this with a better microphone, but until I can re-record it I'm gonna go ahead and put this one up so you can get the meat of the subject. ✍️ EPISODE DESCRIPTION What are GLP‑1s, really? If you've heard the buzz around Ozempic, Wegovy, Mounjaro—or seen headlines claiming they're weight loss miracles—you need to listen to this deep dive before jumping on the bandwagon. In this episode, we break down: What GLP‑1s actually are (hint: yes, they're hormones) Why they work for weight loss and blood sugar control Pros, cons, and legit side effects no one talks about “Ozempic face,” muscle loss, and the long-term cost of shortcuts The truth about hormone therapy (and the hypocrisy of shaming it) Where the research is headed—fertility, mental health, inflammation, and beyond ⚠️ Spoiler: If you're using these meds, you're on hormone therapy. That's not a bad thing—but let's stop pretending it's not what it is. Whether you're curious, concerned, or already prescribed one—this episode gives you facts over fear and the full picture you won't get from TikTok.

In this edition of The Naked Scientists, weight loss jabs being prescribed by GPs in England, but do we know enough about the side effects? Also, a new simple test to replace endoscopies for patients with Barrett's oesophagus. And we hear from one of the engineers at the Vera Rubin Observatory, which is shedding new light on the cosmos... Like this podcast? Please help us by supporting the Naked Scientists

In this episode, we dive into the buzzy world of GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) and how they might do more than just curb appetite, they might help you lose the desire to drink altogether. Dr. Brooke breaks down the science behind how these medications impact your brain's reward system and why they might be a game-changer for the sober-curious. ✨ HIGHLIGHTS: – What exactly are GLP-1s, and how do they work in the body – How these meds may reduce alcohol cravings and “cut the loop” of reward-seeking – Why people on GLP-1s often feel like their drinking habits shift naturally – The double-edged sword: why it's not a magic bullet and how deeper healing still matters – The future of biohacking sobriety with food, supplements, and yes—medications

A man who murdered a grandfather from Tunbridge Wells has been told he'll spend at least 25 years behind bars.Stephen Castle hid Wayne Woodgate's body in woodland after attacking him over a long-standing grudge last October.The 59-year-old from Hastings Road near Matfield was found guilty by a jury following a trial last month.Also in today's podcast, a teenager from Maidstone who left his neighbour with more than 50 stab wounds has been jailed.Police were called to reports of a disturbance at a building in Fairmeadow last September. Hear the moment the 19-year-old was arrested.The prime minister's made big adjustments to his planned welfare reforms following pressure from Labour MPs.It means those with disabilities who currently receive the Personal Independence Payment will continue to get it. It's good news for people like 17 year-old Lukas from Ashford who had his leg amputated because of a rare condition he was born with.A Kent weight loss expert is urging people who've turned to jabs to shed the pounds to make sure they're getting the right support.It's thought around one and a half million people in the UK are using the likes of Mounjaro, Wegovy and Ozempic.Thousands of people are expected at the Historic Dockyard in Chatham tomorrow for Armed Forces Day.There'll be military parades, bands and a service paying tribute to the skill and sacrifice of our armed forces - hear from Medway Council leader Vince Maple who will be there.Football, and Gillingham fans have been planning their season after the fixtures were released.They'll kick off their league two campaign away at Accrington Stanley on August 2nd - we just a full roundup from our sports reporter Luke Cawdell.

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today we're diving into a topic that's been everywhere lately: GLP-1 medications like semaglutide and tirzepatide for weight loss. You may know them by names like Wegovy, Ozempic, Mounjaro, or Zepbound. I want to give you a clear, realistic picture of what to expect—because while the media loves to highlight the dramatic before-and-after photos, the real journey can be slower and more nuanced for some. So in this episode, we're going to talk about the truth—what these medications can do, what they can't, how long things really take, and what you need to know to set yourself up for success. Not hype, not magic promises—just real, honest insight to help you understand the process. Let's get into it. How GLP-1 & GIP/GLP-1 Agonists Work So first things first—how do these meds work? Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist. Basically, they mimic natural hormones in your body that help regulate blood sugar, slow digestion, and—most importantly for weight loss—reduce appetite and improve satiety. That means you feel fuller faster and stay full longer. You're not obsessing over food like before. And that's powerful. But—and this is a big one— these peptides don't magically erase years of weight gain overnight. What they do is help make weight loss easier by reducing hunger and supporting your metabolism—but they don't do all the work for you. It's important to remember they're a powerful tool, not a replacement for your efforts. You're still in control of your choices, habits, and long-term success. Why We Titrate the Dose—and What "Therapeutic Dose" Means Now, let's talk about dosing. When you start Wegovy, you don't start at the highest dose. It's gradually increased over several weeks to give your body time to adjust and to help reduce side effects like nausea or stomach upset. The usual schedule looks like this: You'll start with 0.25 mg once a week for the first month. Then it increases every four weeks—0.5 mg, then 1 mg, then 1.7 mg. By week 17, most people reach the full dose of 2.4 mg once a week—that's the dose shown in studies to lead to the most consistent weight loss, with many people losing around 15% of their total body weight over about a year. But here's the thing—not everyone follows this path exactly, and that's okay. Some people need to slow down or stay longer at a lower dose if they're having side effects. Others may need to increase sooner if they're not seeing appetite changes and are tolerating the medication well. And even though 2.4 mg is considered the “therapeutic dose,” not everyone needs to reach it. Some people feel great and lose weight at a lower dose—and if that's you, that's your sweet spot. The real goal is to find the lowest effective dose that controls your hunger, helps you lose weight at a steady pace, and keeps side effects to a minimum. This isn't a one-size-fits-all journey, and pushing through side effects just to hit the max dose isn't necessary—or safe. Your best dose is the one your body handles well and helps you make progress. *How Much Weight Can You Expect to Lose—and How Fast? Let's take a look at the clinical studies. In large trials, people on semaglutide lost about 15% of their total body weight over 68 weeks. For tirzepatide, it was even higher—20% or more in some cases. But here's the thing—those results happened over a year to a year and a half. Not 6 weeks. Not 3 months. It's a marathon, not a sprint. Also, most of the weight loss doesn't happen during the titration phase. You may see some weight loss early on, especially if your appetite plummets. But the bulk of the weight loss happens once you reach and maintain your therapeutic dose. Why Everyone's Journey Looks Different I can't stress this enough—everybody's journey is different. Some people feel zero hunger from their very first injection. Others don't notice a big change until week 10 or 12. Some drop 10 pounds in the first month. Others lose two pounds and feel discouraged. All of those experiences are normal. Your age, hormones, medications, stress levels, sleep, and past diet history? They all play a role. And let's be real—gaining 20, 50, or 100 pounds didn't happen in a few weeks, right? It likely took months or even years of lifestyle habits, hormonal shifts, emotional eating, or underlying conditions. So we have to give ourselves that same grace and patience when we're trying to take the weight off—even with medical support. Navigating Side Effects and Setbacks Let's talk about the side effects. Nausea, constipation, acid reflux, bloating—yeah, these are pretty common as your body adjusts. And sometimes, those symptoms are your body's way of saying: Hey, slow down. Pushing through intense side effects just to hit a higher dose isn't the goal. In fact, it's not safe. You want the lowest effective dose that keeps your appetite under control, the weight coming off gradually, and your side effects minimal or nonexistent. If you need to pause treatment to let your gut settle or even go back down a dose, that's not failure. That's smart, safe self-care. We're in this for the long haul. Trial and Error with Food—and That's OK One part of this journey that catches people off guard is how sensitive your stomach becomes—especially to certain foods or drinks. Greasy or fried foods, spicy meals, carbonated drinks, alcohol—these can all be triggers for nausea or even vomiting while you're on this medication.  And it makes sense when you think about it: the medication slows down how quickly food and drink leave your stomach. So if you're eating or drinking things that already tend to irritate the stomach lining, the effects can hit harder and last longer. Even if those foods didn't bother you before starting treatment, they might now. It's just one of those things your body has to adjust to, and it may take some trial and error to figure out what still works for you. What is Healthy, Sustainable Weight Loss? So what's a healthy pace of weight loss? In general, 1 to 2 pounds per week is considered safe and sustainable. But on GLP-1s, that might vary. Some weeks you may lose 3 pounds. Some weeks, nothing. And guess what? That's normal. You're looking for overall downward trends, not perfection. The goal here is steady, sustainable fat loss—not dropping weight so quickly that you feel miserable, drained, or start losing muscle. Remember, we're not chasing “skinny”—we're aiming for strong, lean, energized, and healthy. And I know we've talked about this before, but it's worth repeating: exercise is not optional when you're on a GLP-1. It's a must. When you lose weight, you lose both fat and muscle. If you're not actively working to maintain or build muscle, you risk becoming weaker and slowing down your metabolism in the process. We want to keep the muscle you have—and ideally, build more—so your body stays strong and your results last. What Is a “Non-Responder”? Now let's touch on something important: what if the medication doesn't seem to work? Let's talk about what it means to be a “non-responder” on a GLP-1 medication like Wegovy or Zepbound. In clinical terms, a non-responder is someone who has been on their therapeutic dose for at least 3 months and has lost less than 5% of their total body weight—even though they're taking the medication correctly and making lifestyle changes like adjusting their diet, increasing physical activity, and managing stress or sleep. Let's break that down with an example: If someone weighs 200 pounds, 5% of their total body weight would be 10 pounds. So if they've been on their therapeutic dose for 12 weeks and have only lost, say, 4 or 5 pounds—despite doing everything right—they may be considered a non-responder. But as we mentioned before, everyone's therapeutic dose may be different. The therapeutic dose isn't just the maximum dose like 2.4 mg of semaglutide or 15 mg of tirzepatide. It's the dose at which you personally begin to experience consistent appetite suppression, weight loss, and minimal side effects. For some people, that may happen at 1 mg of semaglutide. Others may not feel much of a difference until they reach the full 2.4 mg. Some may even respond better at 1.7 mg and not tolerate the higher dose at all. That's why we titrate slowly, monitor your symptoms, and assess both how you feel and how your body is responding. So how do we know if you've reached your therapeutic dose? We look at things like: Has your appetite significantly decreased? Are you noticing earlier fullness or fewer cravings? Are you losing weight consistently over time Are side effects tolerable or nonexistent? If the answer is yes, you're probably at your therapeutic dose. But if the answer is no—if your hunger hasn't changed much, the scale hasn't moved, and you're not noticing any shift in your eating patterns after 3 months on a stable, higher dose—it might be time to re-evaluate. That could mean adjusting the dose, checking for other health issues that might be interfering (like thyroid problems or certain medications), or even considering a different treatment approach. *So what are my final thoughts?  Your journey is unique. Not everyone responds the same way, and that's okay. The key is finding what works for your body, not just what the label says. These medications can absolutely change lives. But they're not magic. They work with your efforts—not instead of them. You'll need to be patient, flexible, and kind to yourself along the way. You may need to tweak your dose, change your food choices, or give your body time to adjust. That's part of the process. And remember—this isn't just about weight loss. It's about reclaiming your health, confidence, and energy. So take it one step at a time. Celebrate every win. And know that slow progress is still progress. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, be patient, and keep showing up for yourself. And as always, have a happy, healthy week.

You can't inject your way to self-respect. In this controversial and unfiltered episode of Harder Than Life, Kelly Siegel takes on the growing obsession with shortcuts, specifically GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. This isn't a conversation about shame. It's about discipline, ownership, and choosing the harder path that actually builds strength. Whether you're numbing with meds, booze, Netflix, or excuses, this episode will challenge you to get brutally honest about what you're avoiding... and what it's costing you.

From weight medication side effects to the best exercises to build muscle as you age. Ask us anything. We’ve got you covered In this episode, Dr Mariam and Claire Murphy answer all your questions about the body. From whether the BMI is bullshit to knowing what a healthy weight range is. Plus, what’s the right age to start getting bone density checks? They also talk to the experts to answer questions about whether genetics impact your weight and whether you need a special diet and exercise plan if you’re prescribed weight loss medication. They also discuss what kinds of health issues can be reversed if you lose weight and how we reframe conversations about our body. THE END BITS For more information on bone density: Healthy Bones Australia Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. All your health information is in the Well Hub. Support independent women’s media by becoming a Mamamia subscriberCREDITS Hosts: Claire Murphy and Dr Mariam Guest: Dr Isobelle Smith Guest: Dr Jessica McEwan Guest: Dr Sonia Davison Senior Producers: Claire Murphy and Sasha Tannock Audio Producer: Scott Stronach Mamamia studios are styled with furniture from Fenton and Fenton. Visit fentonandfenton.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

GLP-1s can do wonders, but optimizing diet and exercise to the mix maximized their impact. Discover how lifestyle changes can supercharge your results.   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

The mass rollout of weight-loss drugs on the NHS in England began this week as GPs became able to prescribe the drugs for the first time. Some 220,000 people with the ‘greatest need' are expected to receive Mounjaro, the commercial name for tirzepatide, over the next three years.In this episode of the Nursing Standard podcast, Lisa Rickers – a registered nurse with more than 15 years' experience as a bariatric specialist in the NHS – explains that the health benefits of these drugs extend far beyond shedding excess pounds. She also discusses their potential risks, and offers advice for nurses when caring for patients who are using them.Follow the Nursing Standard podcast on Apple Podcasts, Spotify, Acast or wherever you get your podcasts.For more episodes of the Nursing Standard podcast, visit rcni.com/podcast Hosted on Acast. See acast.com/privacy for more information.

Morse code transcription: vvv vvv Met Police chief shocked by planned Palestine Action protest in London Our sister died because of our mums cancer conspiracy theories, say brothers What is the Strait of Hormuz and why does it matter Vera Rubin First celestial image from revolutionary telescope How the US says it hit Irans nuclear sites Mounjaro weight loss jab available at GPs to select few Russias economy is down but not out The Christians drummer has cardiac arrest on Liverpool waterfront stage Bride shot dead in attack on wedding party in south east France Man charged with murder of woman after Stoke Newington gas blast

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube pese a tensiones en Medio Oriente: Futuros en verde: $SPX +0.8%, $US100 +1.2%, $INDU +0.8%. Los rendimientos del Treasury caen levemente. Israel acusó una violación del alto al fuego y amenaza con represalias, mientras Irán niega nuevos ataques. El permiso para civiles de abandonar refugios en Israel trajo algo de alivio. Hoy se publican datos de precios de vivienda, confianza del consumidor y testifica Powell en el Congreso. • IBM despliega sistema cuántico avanzado en Japón: $IBM y el laboratorio RIKEN inauguraron el primer IBM Quantum System Two fuera de EE.UU., ubicado en Kobe. El sistema utiliza el procesador Quantum Heron de 156 cúbits, el más avanzado de la compañía. Apoyado por NEDO, el proyecto busca combinar supercomputación y computación cuántica en la era post-5G. • Novo Nordisk lanza Wegovy en India: $NVO presentó oficialmente su medicamento para pérdida de peso en el mercado indio. Wegovy se venderá en cinco dosis, con un costo mensual entre $50 y $312. La competencia con $LLY se intensifica tras el lanzamiento de Mounjaro en el país. $NVO +1.95% premarket. • Mastercard y Fiserv integran stablecoin FIUSD: $MA fortalece su alianza con $FI al integrar la stablecoin FIUSD en su red global. La plataforma digital de Fiserv se lanzará en 2025 y busca facilitar soluciones para bancos y adquirentes. $FI +6% premarket tras el anuncio. Una jornada con atención en geopolítica, avances tecnológicos y nuevos frentes en salud y pagos digitales. ¡No te lo pierdas!

Morse code transcription: vvv vvv Our sister died because of our mums cancer conspiracy theories, say brothers Met Police chief shocked by planned Palestine Action protest in London How the US says it hit Irans nuclear sites Russias economy is down but not out What is the Strait of Hormuz and why does it matter Bride shot dead in attack on wedding party in south east France The Christians drummer has cardiac arrest on Liverpool waterfront stage Man charged with murder of woman after Stoke Newington gas blast Mounjaro weight loss jab available at GPs to select few Vera Rubin First celestial image from revolutionary telescope

Morse code transcription: vvv vvv Our sister died because of our mums cancer conspiracy theories, say brothers Bride shot dead in attack on wedding party in south east France Met Police chief shocked by planned Palestine Action protest in London How the US says it hit Irans nuclear sites Mounjaro weight loss jab available at GPs to select few Russias economy is down but not out Vera Rubin First celestial image from revolutionary telescope Man charged with murder of woman after Stoke Newington gas blast The Christians drummer has cardiac arrest on Liverpool waterfront stage What is the Strait of Hormuz and why does it matter

Ils étaient réservés aux spécialistes de la nutrition : les médicaments coupe-faim (Wegovy, Mounjaro...) vont désormais pouvoir être prescrits par les généralistes. C'est une erreur : on ne devrait pas prescrire aussi facilement ces médicaments... Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed du 23 juin 2025.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

The Standard's Bill Bowett on the bunker-busting bombs which US President Donald Trump unleashed on Iran.As part of this weekend's offensive, twelve of the bunker buster bombs were used to target three Iranian nuclear sites in Fordow, Natanz and Isfahan.We meet American zoologist Dr Laurie Marker, who has made it her life mission to save the cheetah from extinction.Plus, GPs can prescribe the weight loss jab Mounjaro from today.Also in this episode:Why are activists protesting against Jeff Bezos's Venice wedding festivities?Lightweight material to extract clean drinking water from air.Millions of galaxies shine in first images from the largest camera ever built. Hosted on Acast. See acast.com/privacy for more information.

Welcome back to Diamond Paint and Podcast — where I ramble, reflect, and real-talk my way through a diamond painting session.In this episode, we're all over the place in the best way possible. I'm chatting about:The “Donut Mom” at cheerleading

It's only June. That means you still have six full months to change your life. Seriously. Who do you want to be when the ball drops on December 31st?Are you going to be crying in the bathroom again because nothing fits? Googling “how to lose weight fast” for the hundredth time? Or are you going to feel proud as hell that you didn't give up on yourself this time?In this episode, I'm talking about what's actually possible in six months and how showing up with consistency (not perfection!) can transform how you feel, how you live, and how you see yourself.If you're tired of starting over every Monday, hating your life, emotionally eating your days away, and waiting for “the right time,” this is your wake-up call.Let's talk about who you could be by the end of the year and how to start becoming her now.

Part informative, part a shameless plug for Dr. Seltzers very own product, Apex RX. Find out how adding Essential Amino Acids to your menu can boost results. What are EAA's, what to look for when buying, when to take, and what the benefits are.    APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com      

Nadine Dorries is one of the most recognisable Conservative politicians from the past two decades. Elected as the MP for Mid Bedfordshire in 2005, she notably clashed with David Cameron and George Osborne (who she called ‘two arrogant posh boys') and lost the whip in 2012 when she took part in the reality show I'm A Celebrity, Get Me Out Of Here. Loyal to Boris Johnson, she served in his government and rose to be Culture Secretary. She stood down in 2023 and went on to write about politics in the bestselling books The Plot and Downfall.On the podcast, Nadine tells the Spectator's executive editor Lara Prendergast about her memories of tinned burgers and Sunday lunches as a child, working long shifts as a nurse in Warrington and what it was like spending a year in Zambia. She also explains the ‘relentless' but ‘collegiate' atmosphere of Parliament and how she once saw a mouse at the Commons' salad bar. Nadine explains what it is like to have recently used the weight-loss jab Mounjaro and why, in her family, she is still the ‘queen of the Sunday roast'.Produced by Patrick Gibbons. Hosted on Acast. See acast.com/privacy for more information.

Semaglutide medicines for treating diabetes and obesity (like Ozempic, Wegovy and Mounjaro) have recently been observed to make mice more sedentary. Will these drugs have the same effect on humans? And how were semaglutides discovered, and what does that say about public financing of basic research? Finally, Dr. Bruce A. Scott, a Louisville physician and outgoing President of the American Medical Association gave a fiery address to the association on June 6th. What was he angry about? Here is the full video of Dr. Scott's talk to the AMA: https://www.youtube.com/watch?v=XIEy5ySMDHE ‘Bench Talk: The Week in Science' is a weekly program that airs on WFMP Louisville FORward Radio 106.5 FM (forwardradio.org) every Monday at 7:30 pm, Tuesday at 11:30 am, and Wednesday at 7:30 am. Visit our Facebook page for links to the articles discussed in this episode: https://www.facebook.com/pg/BenchTalkRadio/posts/?ref=page_internal

Nadine Dorries is one of the most recognisable Conservative politicians from the past two decades. Elected as the MP for Mid Bedfordshire in 2005, she notably clashed with David Cameron and George Osborne (who she called ‘two arrogant posh boys') and lost the whip in 2012 when she took part in the reality show I'm A Celebrity, Get Me Out Of Here. Loyal to Boris Johnson, she served in his government and rose to be Culture Secretary. She stood down in 2023 and went on to write about politics in the bestselling books The Plot and Downfall. On the podcast, Nadine tells the Spectator's executive editor Lara Prendergast about her memories of tinned burgers and Sunday lunches as a child, working long shifts as a nurse in Warrington and what it was like spending a year in Zambia. She also explains the ‘relentless' but ‘collegiate' atmosphere of Parliament and how she once saw a mouse at the Commons' salad bar. Nadine explains what it is like to have recently used the weight-loss jab Mounjaro and why, in her family, she is still the ‘queen of the Sunday roast'.  Produced by Patrick Gibbons.

 We know GLP-1 meds are still a hot topic, so wanted to share our journey with you all. We both came to the decision to start taking Zepbound after coming off Mounjaro in 2023. Tune in and listen to why we chose to start Zepbound, what method we are using and what we hope to achieve. In this episode, we also discuss what we learned from Mounjaro just a few years ago to help us prepare for part 2 of this journey. We both spoke to our doctors and explained what we were hoping to achieve and they were both on board. We are THRILLED that medical professionals are willing to help fight this disease of obesity, no matter what it takes! And we are both fortunate enough to have those caring and invested doctors to aid us in this journey. Both doctors covered with us how to properly pull the injection and how to administer it. Explained possible side effects, talked about diet and exercise in a caring and helpful manner. All the things that we deserve as humans in this battle for health! Our advice? If your doctor isn't willing to walk the path with you... FIND A NEW DOCTOR! Like now! The only missing puzzle piece here is to get the insurance companies up to speed. Neither of our insurance companies will cover the drug. So, we had to seek alternate routes to make it affordable. Tune in if you're curious to hear more about that, as we explain it in detail in this episode. We are excited to kick off this new journey and we're looking forward to taking you along for the ride! Follow Justy & Steph on Instagram, where they share their weight loss journey and road to living a happy & healthy lifestyle.@we.are.losing.it If you prefer video to see us talk through our topics, you can watch us on YouTube. https://youtube.com/@wearelosingitShow your support by hitting download, like & subscribe! We truly appreciate each and every one of you!!

Weight loss drugs like Mounjaro and Wegovy aren't just changing bodies - they're rewiring society. Half a million Britons have tried them and that number's soaring. So what will be different in this slim new world? Sunday Times science editor Ben Spencer explains how the drugs are fundamentally altering everything from alcohol to airlines. We also hear Harriet Walker's experience of taking the drugs, and why the expression "on the pen" is now firmly in the vernacular of fashion week. This podcast was brought to you thanks to the support of readers of The Times and The Sunday Times. Subscribe today: http://thetimes.com/thestoryGuests: Ben Spencer, Science Editor, The Sunday Times.Harriet Walker, Fashion Editor, The Times.Host: Manveen Rana.Producer: Olivia Case.Further reading:I tried Ozempic microdosing, the secret way the rich lose weightAll the ways Ozempic will change our world, from alcohol to airlinesClips: Times Radio, Doctor Mike / Youtube, Mark Lewis / YouTube, Fox, @Alexanderweightjourney / YouTube, @DoctorYoun / YouTube, Dr Emma Anders / YouTube, FatOldClimber / YouTube, @ChrisWilx / YouTube, SouthPark / Paramount Plus / Comedy Central, TikTok / Kasiedate, TikTok / @Gabysuecum, TikTok / sistershred. Photo: Romas Foord for The Times magazine. Get in touch: thestory@thetimes.com Hosted on Acast. See acast.com/privacy for more information.

Welcome to the first episode of Diamond Paint and Podcast — a cozy space where I decompress, diamond paint, and talk through the emotional weight of everyday life.This series is for those of us who are just trying to feel like ourselves again one tiny sparkle at a time. No filters, no scripts, no pressure. Just real talk while I work on something that feeds my soul.In this first episode, I'm catching you up on life lately, how I've been feeling, and where my head's been. It's not polished. It's not planned. It's just me decompressing, rambling, and trying to process the chaos with a side of bling!

More and more people with type 1 are using GLP-1 receptor agonists. You know these medications, with brand names like Ozempic, Mounjaro, Wegovy and Zepbound, but none of them are specifically approved to treat T1D. Some of the first studies are underway to study the safety and effectiveness of GLP-1s, but that hasn't stopped thousands of using them off-label or to treat obesity. We're talking to an endocrinologist and a clinical pharmacist about why they prescribe these meds to some of their type 1 patients, who they won't prescribe them for, and – I know you're already asking – how they get insurance coverage.   My guests are endocrinologist Dr. Adam Spitz and Clinical Pharmacist Georgina Farrow GLP news story Stacey references here Dr Spitz's medical thriller here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

You ever lie in bed at night, thinking about all the things you're going to do tomorrow, like wake up early, eat better, clean the house, work out, be more present, but then tomorrow comes… and you're right back in survival mode? Girl, I get it! Please hear this: you're not lazy - you're at maximum capacity. In this episode, I'm getting real about the exhaustion of good intentions that never get met, the emotional weight of feeling stuck, and the shame that sneaks in when you know you're capable of more but can't seem to show up. If you're just getting by and tired of feeling like you're failing… this one's for you.

In this powerful and unapologetic episode, I sit down with Dr. Tyna Moore — physician, author, and outspoken advocate for evidence-based metabolic health — for a deeply candid conversation about peptides, GLP-1s (like Ozempic, Mounjaro, Wegovy, and Zepbound), and why the current medical system is failing women. We dive into: